Humans cannot produce the "exercise hormone" irisin that previous studies reported, a study says.
Previous studies suggested that the hormone irisin, first discovered three years ago, travels from muscle to fat tissue after exercise to tell fat cells to start burning energy instead of storing it.
The finding ignited hope and press coverage that irisin could hold the key to fighting diabetes and obesity, perhaps one day taking the form of a pill that could melt away the pounds without the hassle of a workout.
But new research from an international team of scientists has found that the antibodies used to measure levels of irisin in blood were poorly vetted and non-specific.
"From the start, the study of irisin has been complicated by unvalidated reagents and contradictory data that have raised flags about the existence of irisin and its role in humans and other species," said one of the study authors Harold Erickson, professor at Duke University School of Medicine.
"We provide compelling evidence that the signals reported by previous studies were due to non-specific blood proteins, not irisin. Hopefully, our findings will finally convince other researchers to stop chasing a myth," Erickson noted.
The irisin levels reported by commercial kits were actually due to unknown blood proteins, misconstruing the role of the hormone in human metabolism, the researchers argued.
The study directly tested the antibodies used in previous analyses and showed that they cross-reacted with proteins other than irisin, yielding a false positive result.
Furthermore, none of the proteins detected by these test kits in any human or animal blood samples were the correct size to be irisin.
"Our conclusions make sense, especially in light of the work of other researchers who have shown that the human version of the FDNC5 gene has a deleterious mutation at the beginning," Erickson said.
"Humans can not produce the gene FNDC5, and therefore they can not produce irisin," Erickson added.
The study appeared in the journal Scientific Reports.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
